SmPC: The EU Label and How It Differs From US Labeling

The Summary of Product Characteriztics is the approved product information for a medicine in the European Union. It is the legal basis on which the product is marketed, and it is written for healthcare professionals.

It is approved as part of the marketing authorization: in the EU the label text is part of the authorization itself.

Section structure

The SmPC follows a prescribed section order, and the numbering is stable enough that people cite it directly:

• 1 Name of the medicinal product
• 2 Qualitative and quantitative composition
• 3 Pharmaceutical form
• 4 Clinical particulars, containing therapeutic indications (4.1), posology and administration (4.2), contraindications (4.3), special warnings (4.4), interactions (4.5), fertility, pregnancy and lactation (4.6), effects on driving (4.7), undesirable effects (4.8), overdose (4.9)
• 5 Pharmacological properties
• 6 Pharmaceutical particulars, including shelf life and storage
• 7 Marketing authorization holder
• 8 to 10 Authorization number and dates

Section 4.8 and section 4.4 are where most safety-driven changes land.

The related documents

Package Leaflet (PIL). The patient-facing document, derived from the SmPC and required to be consistent with it. It must also pass user testing for readability, which is an EU-specific requirement with no US equivalent.

Labeling, meaning the text on the carton and immediate packaging.

Together these are the product information, and a change to the SmPC generally cascades into the PIL and often the packaging.

Comparison with US prescribing information

Approved text versus content requirement. The SmPC is approved as part of the authorization. US prescribing information follows the Physician Labeling Rule format, and changes run through the supplement system.

Structure. The SmPC uses numbered sections; PLR format uses Highlights followed by Full Prescribing Information.

Patient information. The EU PIL is mandatory and user-tested. US patient labeling requirements vary by product.

Both derive from the same company core data sheet, which keeps them consistent.

Variations

An SmPC change is a variation, and the type determines the timeline. A safety-driven change to section 4.4 or 4.8 is usually a Type II variation with an assessment period; an administrative change may be Type IA and notifiable.

For a centrally authorized product the variation goes through EMA. For nationally authorized products it goes through each member state, or through the mutual recognition and decentralized procedures, which is why one safety change becomes many national procedures.